NCT07190378Enrolling by invitation
Predictive Factors and Monitoring Strategies in Steroid-Induced Diabetes
Predictive Factors of Steroid-Induced Diabetes and the Role of Continuous Glucose Monitoring in the Diagnosis and Metabolic Control of the Disease
Source: ClinicalTrials.gov · Last updated 1 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Glucocorticoids are widely used in the management of autoimmune, inflammatory and neoplastic conditions. However, they are associated with significant metabolic effects, including steroid-induced diabetes (SID). SID is typically diagnosed using general criteria for type 2 diabetes, which may be inadequate due to the unique glycemic profile often seen in SID, where postprandial hyperglycemia predominates. This research aims to explore the diagnostic value of CGM during steroid therapy and identify risk factors for SID This is a prospective observational study (n=250) enrolling adults initiating glucocorticoid therapy. Participants will undergo 14-day continuous glucose monitoring (CGM) to assess predictive factors and glycemic profile.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 28 Jul 2025
- Start date
- Jun 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Medical University of Warsaw
- Diseases
- Type 2 diabetes
- NCT number
- NCT07190378
What you commit to
- Study type: Observational
- Planned participants: 250
- From Jun 2025 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- GC therapy within the past 6 months
Other illness
- History of diabetes or use of antidiabetic medications
- Replacement therapy for primary or secondary adrenal insufficiency, pituitary insufficiency, Nelson's syndrome, or congenital adrenal hyperplasia
Age
- Age \<18 years
Other
- Lack of consent
Who the study is looking for
- Adults (≥18 years of age)
- No prior diagnosis of diabetes
- Planned initiation of oral and/or intravenous glucocorticoid therapy for non-substitutive indications
- Informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland Coordinator of this site? Confirm its status | Warsaw | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.